Navigation Links
Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
Date:11/24/2008

Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

     CONTACTS:
     For Media Inquiries:               For Cepheid Investor Inquiries:
     Jared Tipton                       Jacquie Ross
     Cepheid Corporate Communications   Cepheid Investor Relations
     408-400-8377                       408-400-8329
     jared.tipton@cepheid.com           jacquie.ross@cepheid.com

'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
2. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
3. Cepheid Reports Record Revenue of $44.8 Million
4. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
7. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
8. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
9. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
10. Accordia Global Health Foundation Receives $12.5 Million Grant From Bill & Melinda Gates Foundation
11. Jon M. Huntsman Receives American Cancer Society Medal of Honor

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...ov. 8 Pharmaceutical Re... Vice President Ken Johnson released the following...bill: ,, "We are disappointed, but not surprise...ons of hardworking Americans as well as nearly hal...ves who voted against the bill. ,, "While well ...
(Date:11/8/2009)... House Passage of Health Care Reform Bill ,, ...prove coverage for all Americans ,, BALTIMORE,...ght the United States House of Representatives pas...ould strengthen Medicare for seniors and end discr...ons of Americans out of affordable health coverage...
(Date:11/7/2009)... 7 The American Medical...irector of Health at the Family Violence Preventio...e today at its semi-annual policy-making meeting. ...hest honor the AMA House of Delegates bestows on a...om.com/cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms...
(Date:11/7/2009)...thful Catholics have a responsibility to vigorousl... status quo." ,, WASHINGTON, Nov. 7 /PRNews...t Judie Brown released the following statement on ...Speaker Nancy Pelosi,s Affordable Health Care for ...serving the status quo for abortion is voted upon....
(Date:11/7/2009)...sume that all youth will rebel, expert says , ...re more likely to behave badly if their parents ex...ts who believe they are simply being realistic mig...cy," Christy Buchanan, a psychology professor at W...said in a university news release. "Negative expec...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors Family Violence Prevention Expert 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2
...studies done at the Yale school of medicine, and r...e get when we eat certain foodstuffs//, like garli...d Wasabi’s. The sensory receptor they ay also unde...receptor drugs used for treatment of cancer, arthr...
... conducted by Columbia University Medical Center h...ded for use in osteoarthritis, could be effective/...l. Until now, drug treatment with Cox-2 inhibitors...geons annually, according to estimates of the Nati...
...ection and treatment of tuberculosis in the state ...tween the public//, private health care sectors an...n organized at Bangalore, as a part of the Interna...ing responsible for poor control of TB in the stat...
...ean breast cancer conference (EBCC-5) had doctors,...cancer research and improve patient care//. Breast...omen. But as of now the survival rates are improvi...on for Research and Treatment of Cancer (EORTC) an...
...l wake up to a fresh dawn tomorrow - A ban that pr... at the crack of dawn// on Sunday. Scotland will a... be the first part of Britain to ban smoking in pu...iven it the sobriquet "sick man of Europe". ...
...China who perceive themselves as being fat, despit...isk of developing depression and school-related st...rs. This could be due to an inclination to Western...different Chinese studies. Teenage girls who said ...
Other Medicine News:Health News:Sodium Hyaluronate Shows Promise In Treatment Of Shoulder Pain 2Health News:Obese Chinese Teens Low On Self-Esteem 2
(Date:11/6/2009)...h., Nov. 6 SCOLR Pharma,...ts for the three and nine months ended September 3... President and CEO, said, "We continue to advance ...ofen formulation. Several potential partners have ... and external resources as they evaluate the poten...
(Date:11/6/2009)...ov. 6 Trius Therapeutics, Inc. ann...ement on Form S-1 with the U.S. Securities and Exc...ial public offering of shares of its common stock....offering will be offered by the Company. ,, Cre...book-running manager, Piper Jaffray & Co. is a...
(Date:11/6/2009).... 6 Caraco Pharmaceutica...ed ketorolac tromethamine ophthalmic solution, 0.5...Drug Administration (FDA) for Sun Pharma,s Abbrevi...r® ophthalmic solution on the first day follo... is therapeutically equivalent to Acular® Oph...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Capital Gold Group Donates to American Red Cross Disaster Relief for Victims of Southern California Wildfires 57552 1Capital Gold Group Donates to American Red Cross Disaster Relief for Victims of Southern California Wildfires 57552 2Fifty Four Percent of Americans Believe Health Care Reform Will Not Be Passed This Year 57547 1Fifty Four Percent of Americans Believe Health Care Reform Will Not Be Passed This Year 57547 2Fifty Four Percent of Americans Believe Health Care Reform Will Not Be Passed This Year 57547 3Fifty Four Percent of Americans Believe Health Care Reform Will Not Be Passed This Year 57547 4DuPont Accelerating Rate of Productivity Through Additional Plant Breeding 14128 1DuPont Accelerating Rate of Productivity Through Additional Plant Breeding 14128 2
... profile of BSI-201 in subjects wi... 15 BiPar Sciences, Inc., a,privately held biopha...ies,today announced that data supporting its lead ...2008 American Society of Clinical Oncology annual,...rom the first in human Phase 1 study of,BSI-201, a...
...ration (NYSE: SGP ), a leader in advancing the sc...HCV) infection, announced today that data from,sev...feron alfa-2b) and,REBETOL(R) (ribavirin, USP) com...ny,s investigational oral HCV protease inhibitor, ...ease Week (DDW) meeting to be held at the San,Dieg...
Other Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
PROFILE Titanium Cannulated Interference Screws
PHANTOM SofThread Cannulated Interference Screws
PHANTOM Absorbable Cannulated Interference Screws
Mini Arthroscope
Medicine Products: